Beta Bionics (NASDAQ:BBNX) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	5	0	2	0	0
Last 30D	0	0	1	0	0
1M Ago	2	0	1	0	0
2M Ago	2	0	0	0	0
3M Ago	1	0	0	0	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.29, a high estimate of $40.00, and a low estimate of $14.00. Highlighting a 15.17% decrease, the current average has fallen from the previous average price target of $32.17.

Deciphering Analyst Ratings: An In-Depth Analysis

A clear picture of Beta Bionics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Jeff Johnson	Baird	Lowers	Neutral	$14.00	$28.00
Jonathan Block	Stifel	Lowers	Buy	$25.00	$31.00
Richard Newitter	Truist Securities	Lowers	Buy	$25.00	$37.00
Mathew Blackman	TD Cowen	Announces	Hold	$17.00	-
Frank Takkinen	Lake Street	Raises	Buy	$40.00	$35.00
Travis Steed	B of A Securities	Raises	Buy	$33.00	$30.00
Richard Newitter	Truist Securities	Raises	Buy	$37.00	$32.00

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Beta Bionics. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Beta Bionics compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Beta Bionics's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Beta Bionics's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Beta Bionics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Beta Bionics Better

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Beta Bionics: Delving into Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Beta Bionics displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 63.14%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Beta Bionics's net margin is impressive, surpassing industry averages. With a net margin of -52.14%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Beta Bionics's ROE excels beyond industry benchmarks, reaching -4.76%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Beta Bionics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.31%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Beta Bionics's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Core of Analyst Ratings: What Every Investor Should Know

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.